1365-2125/asset/olbannerleft.gif?v=1&s=e86b92cac3efbbd2e255b9fa97ece9623eac0b54)
1365-2125/asset/olbannerright.gif?v=1&s=6a7c47d290382bf3bc40c62461bc36a371a081bf)
Pharmacokinetics of ribavirin in patients with hepatitis C virus
Article first published online: 12 JUL 2006
DOI: 10.1111/j.1365-2125.2006.02704.x
Additional Information
How to Cite
Wade, J. R., Snoeck, E., Duff, F., Lamb, M. and Jorga, K. (2006), Pharmacokinetics of ribavirin in patients with hepatitis C virus. British Journal of Clinical Pharmacology, 62: 710–714. doi: 10.1111/j.1365-2125.2006.02704.x
Publication History
- Issue published online: 12 JUL 2006
- Article first published online: 12 JUL 2006
- Received 12 September 2005 Accepted5 April 2006 Published OnlineOpen12 July 2006
- Abstract
- Article
- References
- Cited By
Keywords:
- hepatitis C;
- peginterferon alfa-2a (40KD);
- pharmacokinetics;
- population;
- ribavirin
Aim
A population pharmacokinetic analysis was performed using plasma concentration data (n = 7025) from 380 patients to examine the relationship between ribavirin dose and its pharmacokinetics.
Methods
Ribavirin pharmacokinetics were described by a three-compartment model with sequential zero-order and a first-order absorption processes. Interoccasion variability and food effects were included.
Results
Lean body weight (range 41–91 kg) was the only covariate with a clinically significant influence on ribavirin pharmacokinetics, affecting clearance (15.3–23.9 l h−1) and the volume of the larger peripheral compartment.
Conclusion
The model provided a good description of the available data, confirmed by accurate estimates of parameter values and low residual variability (17%).